GeneDx Holdings Corp. (WGS)
NASDAQ: WGS · Real-Time Price · USD
61.26
+5.11 (9.10%)
At close: Oct 26, 2026, 4:00 PM EDT
62.00
+0.74 (1.21%)
After-hours: Oct 26, 2026, 7:55 PM EDT
GeneDx Holdings Revenue
GeneDx Holdings had revenue of $114.44M in the quarter ending June 30, 2026, with 11.44% growth. This brings the company's total for the last twelve months to $454.43M, up 25.42% year-over-year. In the year 2025, GeneDx Holdings had annual revenue of $427.54M with 39.97% growth. That makes GeneDx Holdings the 11,764th largest company in the world by revenue and 2,346th in the United States.
Revenue (ttm)
$454.43M
Revenue Growth
+25.42%
P/S Ratio
4.02
Revenue / Employee
$349,558
Employees
1,300
Market Cap
1.83B
Revenue by Segment
- Gene Dx 423.09M 99.0%
- Fabric Genomics and Legacy Sema4 4.45M 1.0%
Fiscal year ended Dec 31, 2025 See the full GeneDx Holdings breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 427.54M | 122.09M | 39.97% |
| Dec 31, 2024 | 305.45M | 102.88M | 50.79% |
| Dec 31, 2023 | 202.57M | -32.13M | -13.69% |
| Dec 31, 2022 | 234.69M | 22.50M | 10.60% |
| Dec 31, 2021 | 212.20M | 32.87M | 18.33% |
| Dec 31, 2020 | 179.32M | -16.85M | -8.59% |
| Dec 31, 2019 | 196.17M | 62.83M | 47.12% |
| Dec 31, 2018 | 133.34M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Myriad Genetics | 806.60M |
| NeoGenomics | 766.30M |
| OPKO Health | 587.90M |
| Veracyte | 561.90M |
| CareDx | 458.09M |
| BillionToOne | 397.41M |
| Castle Biosciences | 357.28M |
| Fulgent Genetics | 323.93M |
WGS News
- 3 days ago - GeneDx to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026 - Business Wire
- 6 days ago - GeneDx enhances genome testing portfolio with long-read whole-genome sequencing - TheFly
- 6 days ago - GeneDx announces plans to enhance genome testing portfolio with lrWGS - TheFly
- 6 days ago - GeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing, Advancing Rare Disease Diagnosis - Business Wire
- 7 days ago - GeneDx advances clinical adoption of genomic medicine with 27 abstracts at ASHG - TheFly
- 7 days ago - GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026 - Business Wire
- 19 days ago - GeneDx presents new findings on genomic newborn screening at ICoNS 2026 - TheFly
- 19 days ago - GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026 - Business Wire